Fintel reports that on April 2, 2025, BTIG initiated coverage of NRx Pharmaceuticals (NasdaqCM:NRXP) with a Buy ...

Fintel reports that on March 31, 2025, BTIG upgraded their outlook for Progyny (NasdaqGS:PGNY) from Neutral to Buy. Analyst ...

BTIG says Rocket Companies (RKT) is acquiring Mr. Cooper (COOP) in an all-stock deal valuing Cooper at roughly $143 ore share, plus a $2 cash ...

BTIG analysts highlighted a historical trend suggesting a potential rebound for the S&P 500 (SPX) in April following a ...

Meeting to be held in Dallas on April 8 hosted by BTIG.Don't Miss Our End of Quarter Offers: Discover the latest stocks recommended by top Wall ...

BTIG lowered the firm’s price target on Humacyte (HUMA) to $8 from $10 and keeps a Buy rating on the shares post the Q4 report. The firm cites the company’s increased share count for the ...

The S&P 500's recent breakdown below key technical levels suggests the market’s counter-trend rally may be over, said ...

Shares of CrowdStrike (NASDAQ: CRWD) surged higher on Monday. The move up comes as the S&P 500 and Nasdaq Composite had ...

But Jonathan Krinsky, technical strategist at BTIG, has some potentially good news for equity bulls. Short-term technical signals suggest the S&P 500 and Nasdaq 100 are oversold, he says ...

Jonathan Krinsky, chief market technician at BTIG, sees more slumps for the S&P 500 Index (SPX) forming “W-shape” recoveries, instead of “V-shape” recoveries. The S&P 500 Index (SPX ...

As of March 19, 2025, the average one-year price target for Progyny is $27.71/share. The forecasts range from a low of $23.23 to a high of $35.70. The average price target represents an increase ...